Protein and redox homeostasis in cancer development and therapy

癌症发展和治疗中的蛋白质和氧化还原稳态

基本信息

  • 批准号:
    10413025
  • 负责人:
  • 金额:
    $ 32.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-04-14 至 2024-06-30
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Protein homeostasis (proteostasis) and reduction-oxidation (redox) balance are two tightly regulated and mutually associated molecular events. They play crucial roles in many physiological/pathological conditions including cancer. Disruption of proteostasis and redox balance is an effective approach to selectively kill cancer cells. For examples, proteasome inhibitors such as Bortezomib (Velcade) are highly effective in treating numerous cancers, and autophagy inhibitors are being actively pursued as anti-cancer therapeutics. Many clinically effective chemotherapeutic agents such as arsenic trioxide can induce oxidative burst and cell death, which is believed to contribute, at least in part, to their anti-cancer effectiveness. On the other hand, dysregulated proteostasis and redox homeostasis can contribute to oncogenesis by activating numerous pro- survival/growth signaling pathways. The seemingly paradoxical effects (pro- and anti-cancer) are generally thought to be accounted for by the intensity and duration of the stresses, although the precise underlying mechanisms remain largely elusive. The ubiquitin-binding protein, p62 (SQSTM1), among its numerous functions, critically regulates both proteostasis and redox balance, by sequestering certain proteins in aggregates and delivering them to autophagosomes for degradation. This sequestration function of p62 relies on its dimmerization via the hydrogen bond between lysine (K)7 and aspartate (D)69 residues. We recently reported that TRIM21 (Tripartite motif-containing protein 21), a RING domain-containing ubiquitin E3 ligase, directly interacts with and ubiquitylates p62 at K7 via K63-linkage, which abolishes the K7-D69 hydrogen bond and inhibits p62 oligomerization, aggregation, and sequestration functions. One of the client proteins sequestered by p62 is Keap1, a negative regulator of the antioxidant response that suppresses the antioxidant transcription factor Nrf2. TRIM21-mediated p62 K7 ubiquitylation leads to the failure of Keap1 sequestration and suppressed antioxidant response. Conversely, TRIM21-deficient cells display increased p62 oligomerization, protein aggregation, Keap1 sequestration, Nrf2 activation, and antioxidant response. In this project, we propose to study the hypothesis that TRIM21 functions as a stress-adaptation molecule and plays a crucial role in proteostasis and redox homeostasis, by ubiquitylating p62 and negatively regulating its sequestration function, for the underlying mechanisms and biological significance, with a main focus on anti- cancer therapy and oncogenesis. As TRIM21 expression is dysregulated and correlates with prognosis in numerous cancers, accomplishing this project will uncover TRIM21 as a new important regulator for cellular proteostasis and redox homeostasis, and will help reveal the role of TRIM21 in cancer development and therapy.
项目摘要 蛋白质稳态(proteostasis)和还原-氧化(redox)平衡是两种严格调节的, 相互关联的分子事件。它们在许多生理/病理条件下起着关键作用 包括癌症破坏蛋白质稳态和氧化还原平衡是选择性杀伤的有效途径 癌细胞例如,蛋白酶体抑制剂如硼替佐米(Velcade)在治疗糖尿病方面是高度有效的。 治疗多种癌症,并且自噬抑制剂正被积极地用作抗癌治疗剂。 许多临床有效的化疗药物如三氧化二砷可诱导氧化猝发和细胞凋亡, 死亡,这被认为至少部分地有助于其抗癌效果。另一方面,在一项研究中, 失调的蛋白质稳态和氧化还原稳态可通过激活许多促细胞凋亡的蛋白质, 生存/生长信号通路。看似矛盾的作用(促癌和抗癌)通常是 被认为是由强度和持续时间的压力,虽然精确的基础, 机制在很大程度上仍然难以捉摸。泛素结合蛋白p62(SQSTM 1)是其众多的 功能,严格调节蛋白质和氧化还原平衡,通过隔离某些蛋白质, 聚集并将其递送至自噬体进行降解。p62的这种隔离功能依赖于 通过赖氨酸(K)7和天冬氨酸(D)69残基之间的氢键进行二聚。我们最近 报道了TRIM 21(包含三分基序的蛋白21),一种包含RING结构域的泛素E3连接酶, 通过K63-键直接与K7处的p62相互作用并使其泛素化,这消除了K7-D 69氢键 并抑制p62寡聚化、聚集和隔离功能。其中一种客户蛋白质 被p62隔离的是Keap 1,它是一种抗氧化反应的负调节因子, 转录因子Nrf 2。TRIM 21介导的p62 K7泛素化导致Keap 1螯合失败 抑制抗氧化反应相反,TRIM 21缺陷细胞显示增加的p62 寡聚化、蛋白质聚集、Keap 1螯合、Nrf 2活化和抗氧化反应。在这 项目,我们建议研究的假设,TRIM 21功能作为一种应激适应分子,并发挥作用, 在蛋白质平衡和氧化还原稳态中起关键作用,通过泛素化p62和负调节其 螯合功能,为潜在的机制和生物学意义,主要侧重于抗 癌症治疗和肿瘤发生。由于TRIM 21表达失调并与预后相关, 许多癌症,完成这个项目将揭示TRIM 21作为一个新的重要调节细胞 蛋白质稳态和氧化还原稳态,并将有助于揭示TRIM 21在癌症发展中的作用, 疗法

项目成果

期刊论文数量(44)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Fibronectin growth factor-binding domains are required for fibroblast survival.
Beclin 1 is required for neuron viability and regulates endosome pathways via the UVRAG-VPS34 complex.
  • DOI:
    10.1371/journal.pgen.1004626
  • 发表时间:
    2014-10
  • 期刊:
  • 影响因子:
    4.5
  • 作者:
    McKnight NC;Zhong Y;Wold MS;Gong S;Phillips GR;Dou Z;Zhao Y;Heintz N;Zong WX;Yue Z
  • 通讯作者:
    Yue Z
Diagnosis and prognosis of breast cancer by high-performance serum metabolic fingerprints.
SCCA1/SERPINB3 promotes oncogenesis and epithelial-mesenchymal transition via the unfolded protein response and IL6 signaling.
  • DOI:
    10.1158/0008-5472.can-14-0798
  • 发表时间:
    2014-11-01
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    Sheshadri N;Catanzaro JM;Bott AJ;Sun Y;Ullman E;Chen EI;Pan JA;Wu S;Crawford HC;Zhang J;Zong WX
  • 通讯作者:
    Zong WX
Impaired autophagy, defective T cell homeostasis, and a wasting syndrome in mice with a T cell-specific deletion of Vps34.
  • DOI:
    10.4049/jimmunol.1202071
  • 发表时间:
    2013-05-15
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Parekh VV;Wu L;Boyd KL;Williams JA;Gaddy JA;Olivares-Villagómez D;Cover TL;Zong WX;Zhang J;Van Kaer L
  • 通讯作者:
    Van Kaer L
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wei-Xing Zong其他文献

Wei-Xing Zong的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Wei-Xing Zong', 18)}}的其他基金

Glutamine synthetase in cancer cell metabolism and oncogenesis
谷氨酰胺合成酶在癌细胞代谢和肿瘤发生中的作用
  • 批准号:
    9981701
  • 财政年份:
    2018
  • 资助金额:
    $ 32.24万
  • 项目类别:
PI3 kinase PIK3CB (p110beta) in membrane trafficking and metabolism
膜运输和代谢中的 PI3 激酶 PIK3CB (p110beta)
  • 批准号:
    10001471
  • 财政年份:
    2018
  • 资助金额:
    $ 32.24万
  • 项目类别:
PI3 kinase PIK3CB (p110beta) in membrane trafficking and metabolism
膜运输和代谢中的 PI3 激酶 PIK3CB (p110beta)
  • 批准号:
    10474502
  • 财政年份:
    2018
  • 资助金额:
    $ 32.24万
  • 项目类别:
PI3 kinase PIK3CB (p110beta) in membrane trafficking and metabolism
膜运输和代谢中的 PI3 激酶 PIK3CB (p110beta)
  • 批准号:
    10249278
  • 财政年份:
    2018
  • 资助金额:
    $ 32.24万
  • 项目类别:
Glutamine synthetase in cancer cell metabolism and oncogenesis
谷氨酰胺合成酶在癌细胞代谢和肿瘤发生中的作用
  • 批准号:
    10473698
  • 财政年份:
    2018
  • 资助金额:
    $ 32.24万
  • 项目类别:
Phosphatidylinositol 3-kinases and Autophagy
磷脂酰肌醇 3-激酶和自噬
  • 批准号:
    9205352
  • 财政年份:
    2012
  • 资助金额:
    $ 32.24万
  • 项目类别:
Phosphatidylinositol 3-kinases and Autophagy
磷脂酰肌醇 3-激酶和自噬
  • 批准号:
    8238446
  • 财政年份:
    2012
  • 资助金额:
    $ 32.24万
  • 项目类别:
Phosphatidylinositol 3-kinases and Autophagy
磷脂酰肌醇 3-激酶和自噬
  • 批准号:
    8454422
  • 财政年份:
    2012
  • 资助金额:
    $ 32.24万
  • 项目类别:
Phosphatidylinositol 3-kinases and Autophagy
磷脂酰肌醇 3-激酶和自噬
  • 批准号:
    8606471
  • 财政年份:
    2012
  • 资助金额:
    $ 32.24万
  • 项目类别:
Phosphatidylinositol 3-kinases and autophagy
磷脂酰肌醇 3-激酶和自噬
  • 批准号:
    8469712
  • 财政年份:
    2012
  • 资助金额:
    $ 32.24万
  • 项目类别:

相似海外基金

Establishment of novel osteochondral allografting combined with growth factor- collagen-binding domain fusion technology
新型同种异体骨软骨移植联合生长因子-胶原蛋白结合域融合技术的建立
  • 批准号:
    26462277
  • 财政年份:
    2014
  • 资助金额:
    $ 32.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Translating PTH Therapy as an Adjuvant for Structural Allografting
将 PTH 疗法转化为结构性同种异体移植的佐剂
  • 批准号:
    8344380
  • 财政年份:
    2012
  • 资助金额:
    $ 32.24万
  • 项目类别:
Allografting for Lukemia
白血病同种异体移植
  • 批准号:
    8260361
  • 财政年份:
    2011
  • 资助金额:
    $ 32.24万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7878675
  • 财政年份:
    2009
  • 资助金额:
    $ 32.24万
  • 项目类别:
Composite Allografting for Promoting Survival of Corneal Transplants
复合同种异体移植促进角膜移植的存活
  • 批准号:
    7677758
  • 财政年份:
    2009
  • 资助金额:
    $ 32.24万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7466112
  • 财政年份:
    2008
  • 资助金额:
    $ 32.24万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8010394
  • 财政年份:
    2008
  • 资助金额:
    $ 32.24万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    8208131
  • 财政年份:
    2008
  • 资助金额:
    $ 32.24万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7575273
  • 财政年份:
    2008
  • 资助金额:
    $ 32.24万
  • 项目类别:
Augmenting Antitumor Immunity after Allografting
增强同种异体移植后的抗肿瘤免疫力
  • 批准号:
    7765518
  • 财政年份:
    2008
  • 资助金额:
    $ 32.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了